| A45 | Defining an adipose tissue single cell atlas to understand metabolic disease in HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A9 | Mechanisms of residual immune activation in HIV-1 infected human lymphoid tissue ex vivo | On-demand oral abstract session | Systemic immune activation and inflammation |
| A45 | The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A45 | Higher comorbidity and comedication burden in women and young people living with HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A22 | STAT modulation as strategy to improve NK cell cytotoxicity against HIV and cancer | On-demand oral abstract session | Immunotherapy: Immune-Modifying Agents |
| A21 | Defining CTL immunotherapy candidates against replication-competent and defective HIV | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
| A36 | Immunogens based on VLPs presenting epitopes of the HIV-1 fusion peptide | On-demand oral abstract session | Novel vectors and strategies |
| A6 | Plasma IL-21 associates with HIV-1 Neutralising potency of polyclonal IgG in the periphery | On-demand oral abstract session | Humoral immunity (including broadly neutralizing antibodies) |
| A9 | Novel multiplex analyses reveal disparate natural killer cell signaling pathway activation during lentivirus infection | On-demand oral abstract session | Systemic immune activation and inflammation |
| A17 | HIV modifies the m6A and m5C epitranscriptomic landscape of the host cell | On-demand oral abstract session | Host cellular factors and latency |